Conventional medicine manages what a disease does. Gene therapy targets why it happens. That difference is what makes biotechnology in healthcare the most consequential area of applied biology today, and it is also where the hardest ethical and regulatory questions sit.
Gene therapy modifies or manipulates gene expression, or alters the biological properties of living cells, for therapeutic use.
The Three Mechanisms
- Replacement: substituting a disease-causing gene with a healthy copy
- Silencing: inactivating a harmful gene that is functioning abnormally
- Addition: introducing a new or modified gene to help the body correct or fight a disease
Somatic and Germline: The Central Distinction
| Somatic gene therapy | Germline gene therapy | |
|---|---|---|
| Cells modified | Body cells other than reproductive cells | Sperm, egg, embryo or reproductive-line cells |
| Inheritance | Changes affect only the treated individual | Changes may pass to future generations |
| Status | Focus of current clinical research | Ethically controversial; not permitted for clinical use in India |
The reasons for prohibiting germline therapy are specific: the risk of designer babies, unintended mutations, and irreversible effects on the human gene pool. A somatic error harms one patient. A germline error enters the species.
Somatic therapy operates in two modes.
- In vivo: the therapeutic gene is delivered directly inside the patient’s body
- Ex vivo: cells are removed, genetically modified in the laboratory and returned
Gene Therapy Products
A gene therapy product introduces, modifies, replaces, silences or edits genetic material in human cells. Three components make it up.
| Component | Function |
|---|---|
| Therapeutic gene | The functional DNA, RNA or edited sequence intended to produce benefit |
| Vector | The carrier that delivers genetic material into target cells |
| Regulatory elements | Promoters, enhancers or markers controlling gene expression |
The product types.
| Type | Description |
|---|---|
| Plasmid DNA | Circular DNA engineered to carry therapeutic genes into cells |
| Viral vectors | Modified adenovirus, adeno-associated virus or lentivirus, with disease-causing ability removed |
| Non-viral vectors | Lipid nanoparticles and other synthetic carriers; safer and easier to manufacture, lower delivery efficiency |
| Gene editing products | CRISPR-Cas9, base editing and prime editing to disrupt or repair genes at specific locations |
| Patient-derived cellular products | Cells removed, modified and returned, as in CAR T-cell therapy |
The vector choice is the practical engineering problem in the field. Viruses evolved to enter cells, which makes them efficient carriers and also means the immune system recognises them. Lipid nanoparticles avoid that immune response, which is why they carried the mRNA vaccines, and they deliver less efficiently.
CAR T-Cell Therapy
A patient’s own T cells are removed, engineered to recognise and destroy cancer cells, and reinfused. It is the clearest demonstration that ex vivo modification works in a clinical setting, and it has produced durable remissions in blood cancers that had exhausted other options.
It is also the clearest demonstration of the affordability problem, since a bespoke therapy manufactured for one patient is structurally expensive.
Where the Applications Concentrate
Monogenic disorders are the natural first target, because one defective gene is a tractable objective: haemophilia, sickle cell disease, thalassaemia, muscular dystrophy and inherited retinal disorders.
Cancer is the major research area, largely through engineered immune cells rather than through correcting a single gene, since cancer is polygenic.
For India this ordering matters. Sickle cell disease and thalassaemia have a substantial disease burden here, which makes them the highest-value domestic targets rather than the ones that attract the most global investment.
The Honest Constraints
- Cost. A curative one-time therapy priced beyond the reach of the health systems where the disease is most prevalent is a scientific success and a distributional failure.
- Manufacturing. Cell and gene therapies are made, not merely formulated, and India’s manufacturing capability here lags its strength in generic pharmaceuticals.
- Regulatory capacity. Approving and monitoring advanced therapies requires expertise that is scarce globally and scarcer here.
- Long-term safety data. Durability and late effects are still being established for most approved products.
The Way Forward
- Prioritise sickle cell disease and thalassaemia, where India’s disease burden is largest and the science is furthest advanced.
- Build domestic cell and gene therapy manufacturing, since affordability is a manufacturing problem before it is a pricing problem.
- Strengthen regulatory capacity for advanced therapies, so Indian patients do not wait on foreign approvals.
- Maintain the germline prohibition clearly in statute rather than in guidance.
- Fund long-term patient registries, because the outstanding questions about these therapies are about durability, and only follow-up answers them.
Frequently Asked Questions
What is gene therapy?
A technique that modifies or manipulates gene expression, or alters the biological properties of living cells, for therapeutic purposes. Unlike conventional treatment which usually manages symptoms, gene therapy addresses the genetic or molecular basis of disease.
How does gene therapy work?
Through three broad mechanisms: replacing a disease-causing gene with a healthy copy, inactivating or silencing a harmful gene that is functioning abnormally, or introducing a new or modified gene to help the body correct or fight a disease.
What is the difference between somatic and germline gene therapy?
Somatic gene therapy modifies genes in body cells other than reproductive cells, so changes affect only the treated individual and are not inherited. Germline gene therapy modifies sperm, egg, embryo or reproductive-line cells, so changes may pass to future generations. Somatic therapy is the focus of current clinical research; germline therapy is not permitted for clinical use in India.
What is the difference between in vivo and ex vivo gene therapy?
In vivo therapy delivers the therapeutic gene directly inside the patient’s body. Ex vivo therapy removes cells from the patient, modifies them genetically in the laboratory, and returns them. CAR T-cell therapy is the best-known ex vivo approach.
What is a vector in gene therapy?
A carrier used to deliver genetic material into target cells. Viral vectors use modified viruses whose disease-causing ability has been removed, including adenovirus, adeno-associated virus and lentivirus, because viruses naturally enter cells. Non-viral vectors include lipid nanoparticles and other synthetic carriers, which are often safer and easier to manufacture but less efficient at delivery.
What is CAR T-cell therapy?
A patient-derived cellular gene therapy in which a patient’s own T cells are removed, genetically engineered to recognise and destroy cancer cells, and returned to the body. It is the leading example of ex vivo gene therapy in clinical use.
What are the components of a gene therapy product?
Three: the therapeutic gene or genetic material, meaning the functional DNA, RNA or edited sequence intended to produce benefit; the vector that delivers it; and regulatory elements such as promoters, enhancers or markers that control or optimise gene expression.
Which diseases are the main targets?
Monogenic disorders where a single defective gene causes the condition, including haemophilia, sickle cell disease, thalassaemia, muscular dystrophy and inherited retinal disorders, alongside cancer, which is a major area of research through engineered immune cells.
Practice Questions
Prelims MCQs
- Somatic gene therapy differs from germline gene therapy because
(a) It is cheaper
(b) Its changes are not inherited by future generations
(c) It uses only viral vectors
(d) It targets only cancer
Answer: (b) Somatic therapy modifies non-reproductive cells, so the change affects only the treated individual. - Ex vivo gene therapy involves
(a) Delivering the gene directly into the patient's body
(b) Removing cells, modifying them in the laboratory and returning them
(c) Editing embryos
(d) Using only non-viral vectors
Answer: (b) CAR T-cell therapy is the standard example of the ex vivo approach. - Which of the following is a non-viral vector?
(a) Adenovirus
(b) Lentivirus
(c) Lipid nanoparticles
(d) Adeno-associated virus
Answer: (c) Lipid nanoparticles are synthetic carriers; the other three are viral vectors. - Germline gene therapy in India is
(a) Permitted with approval
(b) Not permitted for clinical use
(c) Permitted only for cancer
(d) Unregulated
Answer: (b) Concerns about designer babies, unintended mutations and irreversible effects on the gene pool have kept it outside clinical permission. - In CAR T-cell therapy, the cells engineered are the patient's
(a) Stem cells
(b) T cells
(c) Red blood cells
(d) Liver cells
Answer: (b) T cells are engineered to recognise and destroy cancer cells, then reinfused.
Mains Questions
- Gene therapy addresses the molecular basis of disease rather than its symptoms. Examine its potential and its limits for India. (250 words)
- The somatic-germline distinction is the central ethical line in gene therapy. Discuss. (150 words)
- Evaluate the regulatory capacity India needs to approve and monitor advanced cell and gene therapies. (250 words)
- Advanced therapies risk being unaffordable in the countries where the diseases they treat are most prevalent. Critically examine. (250 words)
- Discuss the role of vectors in gene therapy and the trade-offs between viral and non-viral delivery. (150 words)
Tell Google you want more of this.
Add Anantam IAS as a preferred sourceOne tap, and this site shows up more often in your own Top Stories, AI Overviews and AI Mode. Remove it any time.
